2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10588R
    Bay K 8644 (Standard) 71145-03-4 98%
    Bay K 8644 (Standard) is the analytical standard of Bay K 8644. This product is intended for research and analytical applications. Bay K 8644 ((±)-Bay K 8644) is a racemate consisting of two isomers (R)-(+)-Bay-K-8644 and (S)-(-)-Bay-K-8644. Bay K 8644 is a L-type Ca2+ channel agonist with an EC50 of 17.3 nM. Bay K 8644 increases Ca2+ influx through sarcolemmal Ca2+ channels by increasing the open time of the channel. Bay K 8644 has vasoconstrictive effects.
    Bay K 8644 (Standard)
  • HY-105978
    CGS 13928C 83348-78-1 98%
    CGS 13928C (Wy-44655) is an angiotensin-converting enzyme (ACE) inhibitor. CGS 13928C effectively inhibits the pressor and blood pressure responses induced by exogenous angiotensin I by blocking the renin-angiotensin system. CGS 13928C exhibits dose-dependent hypotensive activity.
    CGS 13928C
  • HY-106098
    Adibendan 100510-33-6 98%
    Adibendan (BM 14478), a benzimidazole derivative, is an orally active, selective phosphodiesterase III (PDE III) activity inhibitor (IC50=2.0 μM). Adibendan has IC50 values more than 60-fold higher for the inhibition of PDE I or II. Adibendan is a new cardiotonic agent.
    Adibendan
  • HY-106124
    IS-159 133790-13-3 98%
    IS-159 is a potent serotonin 5-HT1 agonist. IS-159 has the potential for the research of migraine.
    IS-159
  • HY-106239
    Fostedil 75889-62-2 98%
    Fostedil (KB 944) is a calcium antagonist that can be used in the research of heart diseases such as angina pectoris.
    Fostedil
  • HY-10626R
    T0901317 (Standard) 293754-55-9 98%
    T0901317 (Standard) is the analytical standard of T0901317. This product is intended for research and analytical applications. T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα. T0901317 activates FXR with an EC50 of 5 μM. T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively. T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice.
    T0901317 (Standard)
  • HY-10627R
    GW3965 (Standard) 405911-09-3 98%
    GW3965 (Standard) is the analytical standard of GW3965 (HY-10627). This product is intended for research and analytical applications. GW3965 is a potent, selective liver X receptor (LXR) agonist with EC50s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively.
    GW3965 (Standard)
  • HY-106306
    Laprafylline 90749-32-9 98%
    Laprafylline (S 9795), a xanthine derivative, is a bronchodilator. Laprafylline has potent anti-bronchoconstrictive effects, inhibiting action on mast cell degranulation and phosphodiesterase (PDE) activity (IC50 of 6 μM).
    Laprafylline
  • HY-10655R
    Palosuran (Standard) 540769-28-6
    Palosuran (Standard) is the analytical standard of Palosuran. This product is intended for research and analytical applications. Palosuran (ACT-058362) is a potent, selective, and orally active antagonist of urotensin II receptor, with an IC50 of 3.6 nM for CHO cell membranes expressing human recombinant receptors. Palosuran can improves pancreatic and renal function in diabetic rats.
    Palosuran (Standard)
  • HY-106562
    Dopexamine 86197-47-9 98%
    Dopexamine is a β2 adrenergic receptor agonist.
    Dopexamine
  • HY-10657R
    SB-706375 (Standard) 733734-61-7
    SB-706375 (Standard) is the analytical standard of SB-706375 (HY-10657). This product is intended for research and analytical applications. SB-706375 is an antagonist of the Urotensin II (UII) receptor. By blocking the Urotensin II receptor, SB-706375 reduces the kidney's response to UII and Urotensin-related peptide (URP) and significantly increases the Glomerular Filtration Rate (GFR). SB-706375 can be used in research on kidney diseases and hypertension.
    SB-706375 (Standard)
  • HY-106682
    Falipamil 77862-92-1 98%
    Falipamil (AQ-A 39), a calcium channel blocker, is a bradycardic agent. The bradycardic effect results from a reduction in the diastolic depolarization rate and a prolongation of the action potential duration.
    Falipamil
  • HY-106684
    Ridazolol 83395-21-5 98%
    Ridazolol is a β-adrenergic receptor (βAR) antagonist. Ridazolol exhibits a high degree of selectivity for β-1 adrenergic receptor (β1AR) and possesses moderate intrinsic sympathomimetic activity (ISA). Ridazolol can competitively antagonize the relaxation effects induced by isoproterenol. Ridazolol is utilized in the research of cardiovascular diseases.
    Ridazolol
  • HY-106699
    Taprostene sodium 87440-45-7 98%
    Taprostene sodium is a partial agonist at prostanoid prostacyclin (IP) receptors. Taprostene sodium interacts additively with Prostaglandin E2 (PGE2) (HY-101952), ONO-AE1-259 (selective EP2 agonist), and acetylcholine. Taprostene sodium exerts a significant cardioprotection.
    Taprostene sodium
  • HY-106700
    Pentisomide 78833-03-1 98%
    Pentisomide (CM 7857), a is an orally active antiarrhythmic agent that blocks sodium channels. Pentisomide processes Vaughan-Williams class I (class I) antiarrhythmic actions.
    Pentisomide
  • HY-106745
    Elziverine 95520-81-3 98%
    Elziverine (Ro 22-4839) is a brain circulation improvement agent with vasospasm antispasmodic effects. Elziverine is a calmodulin antagonist. Elziverine inhibits erythrocyte cell membrane rupture, platelet aggregation and lipid peroxidation.
    Elziverine
  • HY-106766
    DHP-218 102097-78-9 98%
    DHP-218 is a vasodilatory calcium antagonist with pronounced and long-lasting antihypertensive effects .
    DHP-218
  • HY-10678R
    BMS-687453 (Standard) 1000998-59-3 98%
    BMS-687453 (Standard) is the analytical standard of BMS-687453 (HY-10678). This product is intended for research and analytical applications. BMS-687453 is a potent and selective PPARα agonist, with an EC50 and IC50 of 10 nM and 260 nM for human PPARα and 4100 nM and >15000 nM for PPARγ in PPAR-GAL4 transactivation assays.
    BMS-687453 (Standard)
  • HY-106830
    Pelrinone 94386-65-9 98%
    Pelrinone is an orally active cardiotonic agent and PDE III inhibitor with an IC50 of 36 μM. Pelrinone elevates intracellular cAMP levels. The action of Pelrinone is independent of β-adrenergic receptors, and it does not inhibit Na+/K+-ATPase. Pelrinone exerts positive inotropic and vasodilatory effects. Pelrinone inhibits platelet aggregation, reduces thrombus formation, and exerts weak anticoagulant activity without altering hematocrit or circulating platelet counts. Pelrinone can be used in research related to congestive heart failure and coronary thrombosis.
    Pelrinone
  • HY-106831
    R 56865 104606-13-5 98%
    R 56865 is a cardiomyocyte protective agent that protects against digitoxin (Ouabain)-induced myocardial calcium overload. R 56865 has a protective effect against digitoxin-induced intoxication in guinea pig papillary muscle.
    R 56865
Cat. No. Product Name / Synonyms Application Reactivity